Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

944 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outliers of Treatment Frequency in Retinal Vein Occlusion: 24-Month Comparative Analysis of Fight Retinal Blindness! Practitioners.
Ponsioen T, Hashimoto Y, Invernizzi A, Gabrielle PH, Lavid FJ, Mehta H, Silva R, Jaross N, Squirrell D, O'Toole L, Kusenda P, Barthelmes D, Gillies M, Hunt A. Ponsioen T, et al. Among authors: mehta h. Clin Exp Ophthalmol. 2024 Dec 28. doi: 10.1111/ceo.14490. Online ahead of print. Clin Exp Ophthalmol. 2024. PMID: 39731402
Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry.
Hunt AR, Nguyen V, Creuzot-Garcher CP, Alforja S, Gabrielle PH, Zarranz-Ventura J, Guillemin M, Fraser-Bell S, Casaroli Marano RP, Arnold J, McAllister IL, O'Toole L, Gillies MC, Barthelmes D, Mehta H. Hunt AR, et al. Among authors: mehta h. Br J Ophthalmol. 2022 Aug;106(8):1178-1184. doi: 10.1136/bjophthalmol-2020-318491. Epub 2021 Mar 12. Br J Ophthalmol. 2022. PMID: 33712484
Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry.
Hunt AR, Nguyen V, Arnold JJ, McAllister IL, Mehta H, Invernizzi A, Ponsioen T, Gabrielle PH, O'Toole L, Kusenda P, Alforja S, Barthelmes D, Gillies MC. Hunt AR, et al. Among authors: mehta h. Br J Ophthalmol. 2023 Jun;107(6):842-848. doi: 10.1136/bjophthalmol-2021-320482. Epub 2022 Jan 25. Br J Ophthalmol. 2023. PMID: 35078771 Free PMC article.
One-Year Anti-VEGF Therapy Outcomes in Diabetic Macular Edema Based on Treatment Intensity: Data from the Fight Retinal Blindness! Registry.
Mehta H, Gabrielle PH, Hashimoto Y, Kibret GD, Arnold J, Guillaumie T, Kheir WJ, Kok G, Vujosevic S, O'Toole L, Mangelschots E, Jaross N, Ceklic L, Daien V, Viola F, Squirrell D, Lavid FJ, Creuzot-Garcher C, Barthelmes D, Gillies M; Fight Retinal Blindness! Study Group. Mehta H, et al. Ophthalmol Retina. 2024 Sep;8(9):872-879. doi: 10.1016/j.oret.2024.04.008. Epub 2024 Apr 16. Ophthalmol Retina. 2024. PMID: 38615818 Free article.
Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion: Fight Retinal Blindness!
Alforja S, Hunt A, Nguyen V, O'Toole L, Gabrielle PH, Invernizzi A, Mehta H, Ponsioen TL, Squirrell D, Casaroli-Marano RP, Barthelmes D, Gillies MC, Zarranz-Ventura J; Fight Retinal Blindness (FRB) users group. Alforja S, et al. Among authors: mehta h. Ophthalmol Retina. 2024 Oct;8(10):962-970. doi: 10.1016/j.oret.2024.04.014. Epub 2024 Apr 18. Ophthalmol Retina. 2024. PMID: 38641007
944 results